{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C', 'RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain', 'heterophile antibody or monospot testing); Hepatitis E IgM antibody', '5.', 'If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus', '(where needed) [Le Gal, 2005].', '6.', 'PK sample may not be required for participants known to be receiving placebo or non-GSK comparator', 'treatments. Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide the', \"participant's best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot\", 'be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and', 'shipping are in the SPM.', 'Phase III-IV liver chemistry increased monitoring criteria with continued therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'Notify the GSK medical monitor within 24 hours', 'ALT >5x ULN and <8x ULN and', 'of learning of the abnormality to discuss', 'bilirubin <2x ULN without symptoms', 'participant safety.', 'believed to be related to liver injury or', 'Participant can continue study treatment', 'hypersensitivity, and who can be', 'monitored weekly for 2 weeks.', 'Participant must return weekly for repeat liver', 'chemistries (ALT, AST, alkaline phosphatase,', 'OR', 'bilirubin) until they resolve, stabilise or return to', 'ALT >3x ULN and <5x ULN and', 'within baseline', 'bilirubin <2x ULN without symptoms', 'If at any time participant meets the liver chemistry', 'believed to be related to liver injury or', 'stopping criteria, proceed as described above', 'hypersensitivity, and who can be', 'If ALT decreases from ALT >5x ULN and', 'monitored weekly for 4 weeks.', '<8x ULN to >3x ULN but <5x ULN, continue to', 'monitor liver chemistries weekly.', 'If, after 4 weeks of monitoring, ALT <3x ULN and', 'bilirubin <2x ULN, monitor participants twice', 'monthly until liver chemistries normalize or return', 'to within baseline.', 'References', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, et al.', 'Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen Overdose', 'and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', 'Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, D\u00e9ny P, et al. Quantification of', 'Hepatitis Delta Virus RNA in Serum by Consensus Real-Time PCR Indicates Different', 'Patterns of Virological Response to Interferon Therapy in Chronically Infected Patients.', 'J Clin Microbiol. 2005;43:2363-2369.', '90']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '12.5.', 'Appendix 5: COPD Exacerbation Identification,', 'Categorization and Treatment Guidelines', '12.5.1.', 'Guidelines for Identifying COPD Exacerbations', 'The following are symptoms used to ascertain an exacerbation of COPD:', 'Worsening of two or more of the following major symptoms for at least two consecutive', 'days:', 'Dyspnoea', 'Sputum volume', 'Sputum purulence (color)', 'OR', 'Worsening of any one major symptom together with any one of the following minor', 'symptoms for at least two consecutive days:', 'Sore throat', 'Colds (nasal discharge and/or nasal congestion)', 'Fever (oral temperature >37.5 \u00b0C) without other cause', 'Increased cough', 'Increased wheeze', 'Participants who experience worsening COPD symptoms for greater than 24 hours', 'should:', 'Contact their study Investigator and/or research coordinator immediately, and', 'report to the study clinic as required', 'If the participant is unable to contact their study Investigator and/or research', 'coordinator, they should contact their primary care physician (or other health care', 'practitioner as required) and contact their study site as soon as possible', 'If the participant seeks emergency/acute care for worsening respiratory', 'symptoms, he/she should request the caring Health Care Provider (HCP) to', 'contact the Investigator as soon as possible.', 'Participants with worsening respiratory symptoms will be classified as having:', 'A mild/moderate/severe exacerbation and/or pneumonia', 'OR', 'A Lower Respiratory Tract Infection (LRTI)', 'Background variability of COPD', 'A non-respiratory related disease', 'Other respiratory related disease', '91']\n\n###\n\n", "completion": "END"}